> top > docs > PMC:7600245 > spans > 11363-11716 > annotations

PMC:7600245 / 11363-11716 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T39 135-143 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T104 29-35 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T105 37-38 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T105 247-257 Chemical denotes remdesivir http://purl.obolibrary.org/obo/CHEBI_145994
T106 258-263 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T107 347-352 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T84 0-353 Sentence denotes As far as clinical trials in humans, a randomized, placebo-controlled, double-blind trial in hospitalized adults (n = 236) with severe COVID-19 in China initially revealed that the median time to improvement was not substantially different in the remdesivir group (200 mg on the first day, and then 100 mg/day for 9 days) from that of the placebo group.

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
291 29-35 Species denotes humans Tax:9606
303 247-257 Chemical denotes remdesivir MESH:C000606551
318 135-143 Disease denotes COVID-19 MESH:C000657245